Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGenzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
Genzyme, 09/14/09
Genzyme Corporation reported that four–year follow–up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The CAMMS223 Phase 2 trial compared alemtuzumab to an approved MS therapy Rebif® in early, relapsing–remitting multiple sclerosis patients who had received no prior therapy.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor